GIMAP5 Antibody #14108
- WB
- IP
Supporting Data
REACTIVITY | H |
SENSITIVITY | Endogenous |
MW (kDa) | 30,32 |
SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human GIMAP5 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
GTPase immune-associated proteins (GIMAP), also known as immune-associated nucleotide-binding (IAN) proteins, are evolutionarily conserved GTP-binding proteins involved in lymphocyte development, inflammation, and autoimmune diseases (reviewed in 1,2). Human GTPase IMAP family member 5 (GIMAP5, hIan5) is the homolog of the rat Ian4 protein that is mutated in severe cases of T-cell lymphopenia and insulin-dependent diabetes in Biobreeding diabetes-prone (BB-DP) rats (3,4). GIMAP5 protein is preferentially expressed in CD4- and CD8-positive T-cells as well as B-cell lymphomas (4). Research studies using GIMAP5-deficient mice show that GIMAP5 protein is critical for survival of peripheral T-cells, hematopoietic stem cells, and progenitor cells (5-7). Additional studies indicate that GIMAP5 deficiency leads to a loss of immunological tolerance (8). Polymorphisms in the human GIMAP5 gene are associated with systemic lupus erythematosus and type I diabetes (9-11). Potential mechanisms for GIMAP5 control of cell survival include regulation of Bcl-2 family proteins, mitochondrial integrity, lysosomal function, and calcium regulation (5,7, 11-14).
- Nitta, T. and Takahama, Y. (2007) Trends Immunol 28, 58-65.
- Ciucci, T. and Bosselut, R. (2014) Eur J Immunol 44, 348-51.
- Hornum, L. et al. (2002) Diabetes 51, 1972-9.
- Zenz, T. et al. (2004) Genes Immun 5, 109-16.
- Pandarpurkar, M. et al. (2003) Proc Natl Acad Sci U S A 100, 10382-7.
- Schulteis, R.D. et al. (2008) Blood 112, 4905-14.
- Chen, Y. et al. (2011) J Exp Med 208, 923-35.
- Aksoylar, H.I. et al. (2012) J Immunol 188, 146-54.
- Hellquist, A. et al. (2007) J Med Genet 44, 314-21.
- Shin, J.H. et al. (2007) Genes Immun 8, 503-12.
- Lim, M.K. et al. (2009) Lupus 18, 1045-52.
- Keita, M. et al. (2007) Biochem Biophys Res Commun 361, 481-6.
- Wong, V.W. et al. (2010) Self Nonself 1, 259-268.
- Chen, X.L. et al. (2013) Biochem J 449, 353-64.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专